{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:15:17Z","timestamp":1791497717322,"version":"4.3.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Queen's University of Belfast"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Poor adherence to oral antiretroviral therapy (ART) remains an important challenge in the treatment of HIV. Microneedles (MN) potentially could offer a non-invasive long-acting (LA) delivery approach, avoiding the need for daily dosing of ART. However, this claim has yet to be explored amongst its potential end-users. The aim of this mixed methods study was to investigate the perspectives from various end-users surrounding the translation of MN technology to general clinical practice, with a particular focus on delivery of ART. Quantitative postal questionnaires were distributed amongst healthcare professionals (HCPs) and the lay public (LP). A total of 208 responses were obtained (HCP, 69; LP, 139), with a completion rate of 34.7%. The consensus on MN technology was positive from both demographics (HCP, 97.1%; LP, 98.6%), with further strong support of postulated MN use within HIV (HCP, 97.1%; LP, 98.6%). Qualitative focus groups were employed to investigate in-depth, the perspectives of 12 patients with HIV. Again, consensus on MN technology was positive, highlighting benefits pertinent to HIV, including discreet self-application and potential sustained release thus avoiding daily oral ART and associated side effects. Patient concerns focused on the need for varied MN dosing schedules and a reluctance to change from established ART. The findings of this study provide an initial indication of MN acceptability, particularly for use within HIV, from various end-user demographics. Furthermore, concerns raised advocate the importance of continued translational research in this area and should act as motivators for those in MN development to ensure a patient-centred MN product is delivered.<\/jats:p>","DOI":"10.1007\/s13346-020-00848-8","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T14:02:50Z","timestamp":1600437770000},"page":"1199-1217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Exploration into the opinions of patients with HIV, healthcare professionals and the lay public of the use of microneedles in clinical practice: highlighting the translational potential for their role in HIV infection"],"prefix":"10.1007","volume":"11","author":[{"given":"Kurtis","family":"Moffatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caoimhe","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"McCague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0766-4147","authenticated-orcid":false,"given":"Ryan F.","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"848_CR1","unstructured":"UNAIDS. UNAIDS Global HIV and AIDS statistics 2019. 2019. https:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed 14 May 2020."},{"key":"848_CR2","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1097\/00002030-200111090-00006","volume":"15","author":"R Gross","year":"2001","unstructured":"Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15:2109\u201317.","journal-title":"AIDS."},{"key":"848_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/COH.0000000000000002","volume":"8","author":"WR Spreen","year":"2013","unstructured":"Spreen WR, Margolis D, Pottage JC. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS. 2013;8:565\u201371.","journal-title":"Curr Opin HIV AIDS"},{"key":"848_CR4","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","volume":"390","author":"DA Margolis","year":"2017","unstructured":"Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390:1499\u2013510.","journal-title":"Lancet."},{"key":"848_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/COH.0000000000000169","volume":"10","author":"DA Margolis","year":"2015","unstructured":"Margolis DA, Boffito M. Long-acting antiviral agents for HIV treatment. Curr Opin HIV AIDS. 2015;10:246\u201352.","journal-title":"Curr Opin HIV AIDS"},{"key":"848_CR6","first-page":"808","volume":"77","author":"MA Miller","year":"1999","unstructured":"Miller MA, Pisani E. The cost of unsafe injections. Bull World Health Organ. 1999;77:808\u201311.","journal-title":"Bull World Health Organ"},{"key":"848_CR7","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1016\/j.vaccine.2012.05.011","volume":"30","author":"A Taddio","year":"2012","unstructured":"Taddio A, Ipp M, Thivakaran S, Jamal A, Parikh C, Smart S, et al. Survey of the prevalence of immunization non-compliance due to needle fears in children and adults. Vaccine. 2012;30:4807\u201312.","journal-title":"Vaccine."},{"key":"848_CR8","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s11095-016-1885-5","volume":"33","author":"E Larraneta","year":"2016","unstructured":"Larraneta E, McCrudden MTC, Courtenay AJ, Donnelly RF. Microneedles: a new frontier in nanomedicine delivery. Pharm Res. 2016;33:1055\u201373.","journal-title":"Pharm Res"},{"key":"848_CR9","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.addr.2012.04.005","volume":"64","author":"YC Kim","year":"2012","unstructured":"Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012;64:1547\u201368.","journal-title":"Adv Drug Deliv Rev"},{"key":"848_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1365-3156.2010.02510.x","volume":"15","author":"S Merten","year":"2010","unstructured":"Merten S, Kenter E, McKenzie O, Musheke M, Ntalasha H, Martin-Hilber A. Patient-reported barriers and drivers of adherence to antiretrovirals in sub-Saharan Africa: a meta-ethnography. Tropical Med Int Health. 2010;15:16\u201333.","journal-title":"Tropical Med Int Health"},{"key":"848_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jconrel.2018.11.002","volume":"292","author":"MTC McCrudden","year":"2018","unstructured":"McCrudden MTC, Larra\u00f1eta E, Clark A, Jarrahian C, Rein-Weston A, Lachau-Durand S, et al. Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension. J Control Release. 2018;292:119\u201329.","journal-title":"J Control Release"},{"key":"848_CR12","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1177\/193229680800200325","volume":"2","author":"L Heinemann","year":"2008","unstructured":"Heinemann L. The failure of exubera: are we beating a dead horse? J Diabetes Sci Technol. 2008;2:518\u201329.","journal-title":"J Diabetes Sci Technol"},{"key":"848_CR13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s13346-015-0223-5","volume":"5","author":"K Mooney","year":"2015","unstructured":"Mooney K, McElnay JC, Donnelly RF. Paediatricians\u2019 opinions of microneedle-mediated monitoring: a key stage in the translation of microneedle technology from laboratory into clinical practice. Drug Deliv Transl Res. 2015;5:346\u201359.","journal-title":"Drug Deliv Transl Res"},{"key":"848_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/ijpp.12081","volume":"22","author":"K Mooney","year":"2014","unstructured":"Mooney K, McElnay JC, Donnelly RF. Children\u2019s views on microneedle use as an alternative to blood sampling for patient monitoring. Int J Pharm Pract. 2014;22:335\u201344.","journal-title":"Int J Pharm Pract"},{"key":"848_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13346-017-0393-4","volume":"8","author":"HL Quinn","year":"2018","unstructured":"Quinn HL, Hughes CM, Donnelly RF. In vivo and qualitative studies investigating the translational potential of microneedles for use in the older population. Drug Deliv Transl Res. 2018;8:307\u201316.","journal-title":"Drug Deliv Transl Res"},{"key":"848_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11095-010-0101-2","volume":"28","author":"JC Birchall","year":"2011","unstructured":"Birchall JC, Clemo R, Anstey A, John DN. Microneedles in clinical practice-an exploratory study into the opinions of healthcare professionals and the public. Pharm Res. 2011;28:95\u2013106.","journal-title":"Pharm Res"},{"key":"848_CR17","volume-title":"Social research methods","author":"A Bryman","year":"2013","unstructured":"Bryman A. Social research methods. 3rd ed. Oxford: Oxford University Press; 2013.","edition":"3"},{"key":"848_CR18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jclinepi.2006.06.001","volume":"60","author":"R Jones","year":"2007","unstructured":"Jones R. Strength of evidence in qualitative research. J Clin Epidemiol. 2007;60:321\u20133.","journal-title":"J Clin Epidemiol"},{"key":"848_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3102\/0013189X033007014","volume":"33","author":"RB Johnson","year":"2004","unstructured":"Johnson RB, Onwuegbuzie AJ. Mixed methods research: a research paradigm whose time has come. Educ Res. 2004;33:14\u201326.","journal-title":"Educ Res"},{"key":"848_CR20","first-page":"845","volume":"13","author":"AM Clarke","year":"1998","unstructured":"Clarke AM, Jack B. The benefits of using qualitative research. Prof Nurse. 1998;13:845\u20137.","journal-title":"Prof Nurse"},{"key":"848_CR21","first-page":"499","volume":"8","author":"RA Powell","year":"1996","unstructured":"Powell RA, Single HM. Focus groups. Int J Qual Health Care. 1996;8:499\u2013504.","journal-title":"Int J Qual Health Care"},{"key":"848_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.sapharm.2015.07.003","volume":"12","author":"PC Hardigan","year":"2018","unstructured":"Hardigan PC, Popovici I, Carvajal MJ. Response rate, response time, and economic costs of survey research: a randomized trial of practicing pharmacists. Res Soc Adm Pharm. 2018;12:141\u20138.","journal-title":"Res Soc Adm Pharm"},{"key":"848_CR23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1136\/bmj.311.7000.299","volume":"311","author":"J Kitzinger","year":"1995","unstructured":"Kitzinger J. Qualitative research: introducing focus groups. BMJ. 1995;311:299\u2013302.","journal-title":"BMJ."},{"key":"848_CR24","first-page":"218","volume":"55","author":"FH Leung","year":"2009","unstructured":"Leung FH, Savithiri R. Spotlight on focus groups. Can Fam Physician. 2009;55:218\u20139.","journal-title":"Can Fam Physician"},{"key":"848_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.5688\/aj7408141","volume":"74","author":"C Anderson","year":"2010","unstructured":"Anderson C. Presenting and evaluating qualitative research. Am J Pharm Educ. 2010;74:141.","journal-title":"Am J Pharm Educ"},{"key":"848_CR26","unstructured":"Belfast City Council: Belfast facts and figures. 2018. http:\/\/www.belfastcity.gov.uk\/business\/investinginbelfast\/belfast-facts-figures. Accessed 20 June 2018."},{"key":"848_CR27","volume-title":"Survey research methods","author":"J Floyd","year":"2014","unstructured":"Floyd J, Fowler F. Survey research methods. 5th ed. United States: SAGE Publications; 2014.","edition":"5"},{"key":"848_CR28","first-page":"MR000008","volume":"8","author":"PJ Edwards","year":"2009","unstructured":"Edwards PJ, Roberts I, Clarke MJ, Diguiseppi C, Wentz R, Kwan I, et al. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst Rev. 2009;8:MR000008.","journal-title":"Cochrane Database Syst Rev"},{"key":"848_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta5310","volume":"5","author":"E McColl","year":"2001","unstructured":"McColl E, Jacoby A, Thomas L, Soutter J, Bamford C, Steen N, et al. Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients. Health Technol Assess. 2001;5:1\u2013256.","journal-title":"Health Technol Assess"},{"key":"848_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1023\/A:1026218005943","volume":"1","author":"M Carey","year":"1997","unstructured":"Carey M, Morrison-Beedy D, Johnson B. The HIV-knowledge questionnaire: development and evaluation of a reliable, valid, and practical self-administered questionnaire. AIDS Behav. 1997;1:61\u201374.","journal-title":"AIDS Behav"},{"key":"848_CR31","unstructured":"Bourne A, Weatherburn P. The chemsex study. 2014. http:\/\/www.sigmaresearch.org.uk\/chemsex. Accessed 20 August 2019."},{"key":"848_CR32","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1080\/09540121.2012.712667","volume":"25","author":"I Al-dakkak","year":"2013","unstructured":"Al-dakkak I, Patel S, Mccann E, Gadkari A, Prajapati G, Maiese EM. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis. AIDS Care. 2013;25:400\u201314.","journal-title":"AIDS Care"},{"key":"848_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/1055329003252424","volume":"14","author":"PR Garc\u00eda","year":"2003","unstructured":"Garc\u00eda PR, Cote JK. Factors affecting adherence to antiretroviral therapy in people living with HIV\/AIDS. J Assoc Nurses AIDS Care. 2003;14:37\u201345.","journal-title":"J Assoc Nurses AIDS Care"},{"key":"848_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1089\/apc.2006.20.359","volume":"20","author":"LS Rintamaki","year":"2006","unstructured":"Rintamaki LS, Davis TC, Skripkauskas S, Bennett CL. Social stigma concerns and HIV medication adherence. AIDS Patient Care STDs. 2006;20:359\u201368.","journal-title":"AIDS Patient Care STDs"},{"key":"848_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1086\/313849","volume":"30","author":"MA Chesney","year":"2000","unstructured":"Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30:171\u20136.","journal-title":"Clin Infect Dis"},{"key":"848_CR36","first-page":"002","volume":"1","author":"SE Kahema","year":"2018","unstructured":"Kahema SE, Mgabo MR, Emidi B, Sigalla GN, Kajeguka DC. Factors influencing adherence to antiretroviral therapy among HIV infected patients in Nyamagana-Mwanza, Northern Tanzania: a cross sectional study. Int Arch Med Microbiol. 2018;1:002.","journal-title":"Int Arch Med Microbiol"},{"key":"848_CR37","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2013.09.030","volume":"155","author":"CW Hendrix","year":"2013","unstructured":"Hendrix CW. Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design. Cell. 2013;155:515\u20138.","journal-title":"Cell."},{"key":"848_CR38","doi-asserted-by":"publisher","first-page":"e005717","DOI":"10.1136\/bmjopen-2014-005717","volume":"4","author":"I Young","year":"2014","unstructured":"Young I, Flowers P, McDaid LM. Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: findings from a qualitative study in Scotland. BMJ Open. 2014;4:e005717.","journal-title":"BMJ Open"},{"key":"848_CR39","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1080\/13691058.2017.1380230","volume":"20","author":"M Thomann","year":"2018","unstructured":"Thomann M, Grosso A, Zapata R, Chiasson MA. \u201cWTF is PrEP?\u201d: attitudes towards pre-exposure prophylaxis among men who have sex with men and transgender women in New York City. Cult Health Sex. 2018;20:772\u201386.","journal-title":"Cult Health Sex"},{"key":"848_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/jan.13818","volume":"75","author":"J McLenon","year":"2019","unstructured":"McLenon J, Rogers MAM. The fear of needles: a systematic review and meta-analysis. J Adv Nurs. 2019;75:30\u201342.","journal-title":"J Adv Nurs"},{"key":"848_CR41","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jconrel.2018.07.009","volume":"285","author":"EM Migdadi","year":"2018","unstructured":"Migdadi EM, Courtenay AJ, Tekko IA, Mccrudden MTC, Kearney M, Mcalister E, et al. Hydrogel-forming microneedles enhance transdermal delivery of metformin hydrochloride. J Control Release. 2018;285:142\u201351.","journal-title":"J Control Release"},{"key":"848_CR42","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s11095-014-1301-y","volume":"31","author":"RF Donnelly","year":"2014","unstructured":"Donnelly RF, Moffatt K, Alkilani AZ, Vicente-P\u00e9rez EM, Barry J, McCrudden MTC, et al. Hydrogel-forming microneedle arrays can be effectively inserted in skin by self-application: a pilot study centred on pharmacist intervention and a patient information leaflet. Pharm Res. 2014;31:1989\u201399.","journal-title":"Pharm Res"},{"key":"848_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40271-015-0151-y","volume":"9","author":"M Serpell","year":"2016","unstructured":"Serpell M, Tripathi S, Scherzinger S, Oksche A, Wilson M. Assessment of transdermal buprenorphine patches for the treatment of chronic pain in a UK observational study. Patient. 2016;9:35\u201346.","journal-title":"Patient."},{"key":"848_CR44","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3389\/fphar.2017.00831","volume":"8","author":"SA Iacob","year":"2017","unstructured":"Iacob SA, Iacob DG, Jugulete G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment - clinical points of view and practical considerations. Front Pharmacol. 2017;8:831.","journal-title":"Front Pharmacol"},{"key":"848_CR45","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.vaccine.2014.01.076","volume":"32","author":"JJ Norman","year":"2014","unstructured":"Norman JJ, Arya JM, McClain MA, Frew PM, Meltzer MI, Prausnitz MR. Microneedle patches: usability and acceptability for self-vaccination against influenza. Vaccine. 2014;32:1856\u201362.","journal-title":"Vaccine."},{"key":"848_CR46","unstructured":"Ham RJ, Sloane PD. Ham\u2019s primary care geriatrics: a case-based approach. 6th ed. Philadelphia: Elsevier - Health Sciences Division; 2014."},{"key":"848_CR47","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cger.2012.01.008","volume":"28","author":"ZA Marcum","year":"2012","unstructured":"Marcum ZA, Gellad WF. Medication adherence to multidrug regimens. Clin Geriatr Med. 2012;28:287\u2013300.","journal-title":"Clin Geriatr Med"},{"key":"848_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1300\/J017v25n03_01","volume":"25","author":"J Cohen-Mansfield","year":"2007","unstructured":"Cohen-Mansfield J, Biddison J. The scope and future trends of gerontechnology: consumers\u2019 opinions and literature survey. J Technol Hum Serv. 2007;25:1\u201319.","journal-title":"J Technol Hum Serv"},{"key":"848_CR49","doi-asserted-by":"publisher","DOI":"10.4324\/9780203506301","volume-title":"Qualitative educational research in action: doing and reflecting","author":"T O\u2019Donoghue","year":"2003","unstructured":"O\u2019Donoghue T, Punch K. Qualitative educational research in action: doing and reflecting. 1st ed. London: Falmer Press; 2003.","edition":"1"},{"key":"848_CR50","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/bioe.12378","volume":"32","author":"P Hutchinson","year":"2018","unstructured":"Hutchinson P, Dhairyawan R. Shame and HIV: strategies for addressing the negative impact shame has on public health and diagnosis and treatment of HIV. Bioethics. 2018;32:68\u201376.","journal-title":"Bioethics"},{"key":"848_CR51","doi-asserted-by":"publisher","first-page":"e029747","DOI":"10.1136\/bmjopen-2019-029747","volume":"9","author":"T Hildebrandt","year":"2019","unstructured":"Hildebrandt T, Bode L, Ng JSC. Effect of lifestyle stigma on public support for NHS-provisioned pre-exposure prophylaxis (PrEP) and preventative interventions for HPV and type 2 diabetes: a nationwide UK survey. BMJ Open. 2019;9:e029747.","journal-title":"BMJ Open"},{"key":"848_CR52","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.drudis.2017.10.013","volume":"23","author":"RF Donnelly","year":"2018","unstructured":"Donnelly RF, Larra\u00f1eta E. Microarray patches: potentially useful delivery systems for long-acting nanosuspensions. Drug Discov Today. 2018;23:1026\u201333.","journal-title":"Drug Discov Today"},{"key":"848_CR53","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1365-2929.2006.02418.x","volume":"40","author":"B DiCicco-Bloom","year":"2006","unstructured":"DiCicco-Bloom B, Crabtree BF. The qualitative research interview. Med Educ. 2006;40:314\u201321.","journal-title":"Med Educ"},{"key":"848_CR54","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/13645570701401305","volume":"11","author":"C Noy","year":"2008","unstructured":"Noy C. Sampling knowledge: the hermeneutics of snowball sampling in qualitative research sampling knowledge. Int J Soc Res Methodol. 2008;11:327\u201344.","journal-title":"Int J Soc Res Methodol"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-020-00848-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-020-00848-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-020-00848-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T23:45:09Z","timestamp":1631922309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-020-00848-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["848"],"URL":"https:\/\/doi.org\/10.1007\/s13346-020-00848-8","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,18]]},"assertion":[{"value":"28 August 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for the study was granted from the School of Pharmacy Ethics Committee at Queen\u2019s University prior to commencement (016PMY2018).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ryan Donnelly is an inventor of patents that have been licensed to companies developing microneedle-based products and is a paid advisor to a number companies working towards commercialisation of this technology. The resulting potential conflict of interest has been disclosed and is managed by Queen\u2019s University Belfast. The companies had no role in the design of the study, in the collection, analyses or interpretation of data, in the writing of the manuscript or in the decision to publish the results. No other authors have any competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients and participants for being included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}